Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study to Evaluate the Effect of Genotype on LY2216684
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT01460381
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 67
- Registration Number
- NCT01460368
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
A Study to Evaluate the Effect of Clarithromycin on LY2216684
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 14
- Registration Number
- NCT01460407
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States
A Non-drug Methods Study in Participants With Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Other: PET scan using florbetapirOther: MRI Scan
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 56
- Registration Number
- NCT01459016
- Locations
- 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vic-En-Bigorre, France
A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Ortho-CyclenBiological: Dulaglutide
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 22
- Registration Number
- NCT01458210
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
A Study in Participants With Type I Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1114
- Registration Number
- NCT01454284
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oxford, United Kingdom
A Study of LY2484595 in Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- Drug: LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)Drug: LY2484595 Reference Formulation (RF)
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 39
- Registration Number
- NCT01450098
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, California, United States
A Study of LY3031207 in Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2011-10-10
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 29
- Registration Number
- NCT01449630
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States
A Study of LY2484595 on Pharmacokinetics in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 82
- Registration Number
- NCT01448824
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
- Conditions
- Recurrent Gliomas
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 58
- Registration Number
- NCT01445119
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States